Acrivon Q2 2026 net loss $18.0M; cash $90.0M funds into Q4 2027

Acrivon Therapeutics, Inc.

2026-Q2 EPS reported -$0.92

Net loss $18.0M vs $21.0M in Q2 2025; R&D expense $13.8M vs $16.2M prior year.
Cash, equivalents and investments $90.0M as of Jun 30, 2026, expected to fund ops into Q4 2027.
ACR-368 Phase 2b prespecified interim analysis in serous EC on track for H2 2026; Phase 3 initiation planned H1 2027.
ACR-2316 entered randomized dose expansion at 120mg and 160mg oral QD in AP3-prioritized tumor types.
IND filing for CDK11 inhibitor candidate planned H1 2027; additional AP3 programs to start in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.